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ABSTRACT
We recently established a critical role for the growth factor progranulin in
bladder cancer insofar as progranulin promotes urothelial cancer cell motility
and contributes, as an autocrine growth factor, to the transformed phenotype by
modulating invasion and anchorage-independent growth. In addition, progranulin
expression is upregulated in invasive bladder cancer tissues compared to normal
controls. However, the molecular mechanisms of progranulin action in bladder cancer
have not been fully elucidated. In this study, we searched for novel progranulininteracting proteins using pull-down assays with recombinant progranulin and
proteomics. We discovered that drebrin, an F-actin binding protein, bound progranulin
in urothelial cancer cells. We characterized drebrin function in urothelial cancer cell
lines and showed that drebrin is critical for progranulin-dependent activation of the
Akt and MAPK pathways and modulates motility, invasion and anchorage-independent
growth. In addition, drebrin regulates tumor formation in vivo and its expression is
upregulated in bladder cancer tissues compared to normal tissue controls. Our data
are translationally relevant as indicate that drebrin exerts an essential functional
role in the regulation of progranulin action and may constitute a novel target for
therapeutic intervention in bladder tumors. In addition, drebrin may serve as novel
biomarker for bladder cancer.

invasive disease. For invasive tumors instead, prognosis
is much less favorable, with only 50% survival at 5 years.
Invasive tumors frequently progress to life-threatening
metastases, which are associated with a 5 year survival
rate of ~6% [2]. Thus, understanding the mechanisms that
regulate bladder tumor invasion and progression toward
metastasis is critical to predict and treat this devastating
condition in bladder cancer patients.
The growth factor progranulin, also known as
proepithelin, PCDGF, granulin-epithelin precursor or
acrogranin, is a secreted glycoprotein which plays an

INTRODUCTION
Bladder cancer (BC) is one of the most common
cancers in the United States with 56,390 estimated new
cases and 11,170 estimated deaths in 2014 [1]. Bladder
tumors show diverse histopathological patterns and
clinical behaviors [2] making this a serious hindrance in
the management of bladder tumors. The clinical stage of
BC is dependent on the depth of tumor invasion [3] and,
although the prognosis for low-grade tumors is generally
good, 10%–15% of these patients will later develop
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important role in cell proliferation, wound healing and
transformation in several cancer model systems [4–6].
In addition, progranulin regulates inflammation and
neurodegeneration [7] and low levels of circulating
progranulin are associated with fronto-temporal dementia
(FTD). Progranulin interacts with the protein core of the
heparan sulfate proteoglycan perlecan and it has been
suggested that this interaction leads to a pro-angiogenic
and proinvasive phenotype [8]. We have discovered
that progranulin plays a critical role in bladder cancer
by promoting urothelial cancer cell motility [9], and
demonstrated that progranulin contributes as an autocrine
growth factor to the transforming phenotype by regulating
invasion and anchorage-independent growth [10, 11]. In
addition, progranulin is overepressed in invasive bladder
cancer tissues vis-à-vis non-neoplastic tissues and it is
detectable in the urine [11]. Thus, progranulin may be critical
for the transition to the invasive phenotype in bladder cancer
and may serve as a novel biomarker for bladder cancer.
Despite the increasing interest in progranulin
biology, progranulin’s mode of action is still poorly
characterized. Furthermore, very few proteins that mediate
the early stages of progranulin signaling from the plasma
membrane have been so far characterized.
Previous studies have identified proteins of ~130
kDa as putative progranulin receptors [12, 13] and
more recently, sortilin has been identified as a novel
progranulin-interacting protein using membrane binding
with alkaline phosphatase-labeled progranulin. Sortilin is
a single-pass Type I transmembrane protein of the Vps10
family that is localized to the cell surface, secretory,
and endocytic compartments of eukaryotic cells [14].
However, sortilin acts as negative regulator of progranulin
levels and signaling by targeting progranulin for lysosomal
degradation [14].
Progranulin has been shown to bind TNF receptors
1 and 2 and decrease TNF-dependent activation of MAPK
(ERKs, p38 and JNK) by disturbing the TNF/TNFR
interaction [15]. These results therefore do not support a
role of TNFRs as bona fide progranulin signaling interacting
partner. In addition, more recent papers have challenged the
physical and functional interaction between progranulin
and TNFRs [16], suggesting that additional experiments are
necessary to clarify these contradictory results. In addition,
in the presence of CpG-ONDs progranulin proteolytic
fragments are soluble cofactors for Toll-like receptor 9
(TLR9) and contribute to innate immunity [17]. Furthermore,
Tropomyosin 3 has been more recently reported as a novel
progranulin-interacting protein in hepatocellular carcinoma
cells [18], but the biological significance of this interaction
has not been yet fully characterized.
In search for novel progranulin interacting proteins
we performed pull-down assays with recombinant
progranulin and protein extracts of 5637 bladder cancer
cells. Proteomic analysis identified the F-actin-binding
protein drebrin (developmentally regulated brain protein)
www.impactjournals.com/oncotarget

[19, 20] as a novel progranulin-binding partner. We have
characterized the biological significance of this interaction
in invasive bladder cancer cells and showed that drebrin
is critical for the regulation of progranulin-induced cell
motility and invasion by mediating progranulin-induced
F-acting remodeling. Furthermore, drebrin is essential
for progranulin-induced activation of the Akt and MAPK
signaling pathways. Significantly, drebrin depletion in
tumorigenic urothelial cancer cells inhibits motility,
anchorage-independent growth and tumor formation in
vivo. In addition, drebrin is upregulated in high grade
bladder cancer tissues compared to lower grade and
normal tissue controls.
Collectively, we have identified drebrin as a novel
progranulin-interacting protein and presented evidences
that support a critical role for drebrin in regulating
progranulin-dependent signaling and biological responses
in bladder cancer.

RESULTS
Progranulin interacts with drebrin
In a search for novel progranulin interacting pro
teins we performed pull-down assays with recombinant
progranulin and protein extracts of 5637 bladder cancer
cells. Samples were separated by SDS-PAGE, visualized
with Coomassie blue staining and processed for mass
spectrometry. Proteomic analysis of selected bands
(Figure 1A, arrow) identified the neuronal F-actin-binding
protein drebrin (developmentally regulated brain protein) [19,
20] as a novel progranulin-interacting protein (Figure 1A,
arrow). Next, we confirmed by immunoblotting that drebrin
was expressed in various bladder cancer cells (Figure 1B)
with a plasma membrane distribution in 5637 invasive
urothelial cancer cells (arrows, Figure 1C). To further
validate the interaction between progranulin and drebrin,
we performed confocal microscopy analysis. We detected
drebrin colocalization with progranulin in punctate vesicles
(Figure 1D) suggesting that this interaction occurs upon
progranulin internalization from cell membrane. The
colocalization was further validated by line scanning confocal
(bottom panel of Figure 1D), strongly supporting the notion
that drebrin is a novel binding partner of progranulin.
Next, we confirmed the interaction between
progranulin and endogenous drebrin by co-immuno
precipitation assays in 5637 cells (Figure 2A). Drebrin
was detectable in complex with endogenously expressed
progranulin at low levels in unstimulated cells and
this association decreased after 5 min of progranulin
stimulation (Figure 2A, 5’). On the contrary, 30 min
of progranulin stimulation strongly enhanced the
progranulin/drebrin interaction (Figure 2A, 30’).
Drebrin was not detectable when lysates of 5637 cells
were immunoprecipitated with an unrelated antibody used
as control (Figure 2A, IgG). These results were confirmed
10826
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Figure 1: Progranulin interacts with the F-acting-binding protein drebrin. (A) Proteomic identification of drebrin from 5637
cell extract pulled-down with recombinant His-tagged progranulin. Samples were separated by SDS-PAGE, visualized with Coomassie
blue staining and processed for mass spectrometry. Bands isolated from gel and analyzed are identified by the arrow. Drebrin identity was
confirmed on a local Mascot server against the Swissprot database. (B) Drebrin immunodetection from lysates of various urothelial-carcinoma
cell lines (Upper panel). B-actin was used as a loading control (lower panel). The blot is representative of two independent experiments.
(C) Representative images of immunofluorescence analysis of drebrin expression in 5637 cells. Arrows show drebrin localization at the
membrane. DAPI staining was used to label cell nuclei. (D) Drebrin colocalizes with progranulin after 5 min of stimulation as determined
by confocal microscopy. Notice the distinct co-localization of drebrin and progranulin in the Z stacks (yellow staining, bottom right panel).
The line-scanned profiles at the bottom of the fluorescence images show the distribution of the fluorescence signals of each channel between
the white arrows in the corresponding confocal images. Pictures are representative of at least 10 independent fields from three independent
experiments. An average of 300 cells was examined for each condition.
by repeating coimmunoprecipation experiments in T24
cells, where we detected the same kinetics of association
between progranulin and endogenous drebrin (Figure 2B).
Longer exposure of progranulin blots are included to
show endogenous progranulin in total lysates (Figure
2A and 2B). To confirm the results obtained by antiprogranulin antibodies, we performed reciprocal co-IP
and immunoprecipitated the complex using a nti-drebrin
antibodies. We tried two commercially available anti
bodies but both antibodies showed an extremely low
ability to immunoprecipitate endogenous drebrin, thus
preventing us in detecting progranulin in complex with
drebrin. (Not shown)
www.impactjournals.com/oncotarget

Collectively, these results indicate that drebrin
complexes with progranulin and may play a role in
regulating progranulin-induced biological responses in
bladder cancer cells.

Drebrin regulates progranulin-induced
biological responses in urothelial cancer cells
We have previously established the critical role of
progranulin in promoting motility of bladder cancer cells
[10, 11]. Thus, as an initial step to determine drebrin
function in progranulin-mediated responses in urothelial
cancer cells, we transiently depleted endogenous drebrin
10827
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Figure 2: Progranulin coprecipitates with drebrin in 5637 and T24 urothelial cancer cells. (A) Serum-starved (SFM) 5637
and (B) T24 cells were stimulated with recombinant progranulin (80 nM) for 5 and 30 min (5’ and 30’). progranulin interaction with drebrin
was assesses by coimmmunoprecipitation experiments. 3 mg of lysates from 5637 (A) and T24 (B) cells were immunoprecipitated with
anti-progranulin polyclonal antibodies. Unrelated IgG (IgG) was used as control (A) Drebrin was detected by immunoblot using antidrebrin monoclonal antibodies. Blots are representative of two independent experiments.
www.impactjournals.com/oncotarget
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in 5637 and T24 cells by siRNA approaches and assessed
cell migration. We achieved about ~90 and 75% depletion
of endogenous drebrin in 5637 (Figure 3A) and T24
(Figure 3B) cells, respectively as compared to cells treated
with either vehicle or scrambled siRNA. Suppression of
drebrin expression led to a robust inhibition of migration
in both cell lines in response to progranulin stimulation
(Figure 3A and 3B).
As drebrin is important for progranulin-evoked cell
migration, we hypothesized that drebrin may also regulate
the ability of urothelial cancer cells to invade through a 3D
extracellular matrix upon progranulin stimulation. Thus,
we used Matrigel-coated filters to examine invasive ability
of 5637 cells depleted of endogenous drebrin (Figure 3C).
Following exposure to progranulin (40 nM), there was a
marked increase in the ability of vehicle- and control oligotransfected 5637 cells to invade a 3D matrix (Figure 3D)
while drebrin knock-down significantly (**p < 0.01) reduced
the invasive capacity of these cells (Figure 3D).
As progranulin-induced motility and invasion
requires the activation of Akt and MAPK pathways
[9–11], we sought to determine whether drebrin may
regulate progranulin-dependent signaling and assessed by

immunoblotting Akt and ERK1/2 activation in drebrindepleted 5637 cells (Figure 3E). Drebrin knockdown almost
completely abolished progranulin-induced Akt activation,
and caused > 50% reduction in ERK1/2 phosphorylation
as compared to vehicle or siRNA control-transfected 5637
cells (Figure 3E). The negative effect of drebrin depletion
on progranulin signaling was reproducible in T24 cells but
it more severely affected ERK1/2 activation as compared to
Akt signaling (data not shown).
These results indicate that drebrin is a critical protein
component for progranulin-mediated activation of Akt/
MAPK pathways leading to cell migration and invasion
and may indeed function as an essential component of a
progranulin signaling complex in bladder cancer cells.

Drebrin modulates progranulin-induced actin
cytoskeleton remodeling
Cancer cell motility and invasion require a change
in cellular morphology associated with actin remodeling
[21, 22]. Because drebrin binds F-actin [19, 20], we
investigated whether progranulin stimulation of 5637
cells would affect the ability of drebrin to bind F-actin

Figure 3: Drebrin modulates progranulin-induced motility and signaling of urothelial cancer cells. (A and B) 5637 and
T24 cells were transiently transfected with vehicle, control oligos or On-Target siGenome pool of drebrin-specific oligos. 48 h posttransfection cells were transferred to SFM or SFM supplemented with progranulin (40 nM) and counted for migration after 18 h. Data are
the average of three independent experiments ±SD. *P < 0.05; **P < 0.01. Drebrin levels were assessed by immunoblotting with antidrebrin polyclonal antibodies. Densitometric analysis is expressed as arbitrary units. (C) Drebrin-depleted 5637 cells were assessed for
invasive ability through Matrigel (D) as described in Materials and Methods. Data are the average of three independent experiments ±SD.
**P < 0.01. (E) Activation of Akt and ERK1/2 in drebrin-depleted 5637 cells was determined by immunoblotting using phospho-specific
antibodies. Densitometric analysis is expressed in arbitrary units. Blot is representative of three independent experiments.
www.impactjournals.com/oncotarget
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and mediate actin remodeling. To this end, we transiently
transfected a GFP-tagged drebrin protein and assessed
by immunofluorescence analysis the resultant F-actin
network, visualized by rhodamine-phalloidin labeling.
In serum-starved 5637 cells, full length GFP-drebrin
(residue 1–707) staining was diffuse in the cytoplasm
and colocalized with cortical F-actin (Figure 4A,
arrows). Interestingly, progranulin stimulation induced
redistribution of drebrin in F-actin-enriched spikes [23]
at the membrane edge of 5637 cells (Figure 4A, arrows).
To further confirm the role of drebrin in regulating
progranulin-induced F-actin remodeling, we depleted 5637
cells of endogenous drebrin and analyzed F-actin network
by rhodamine-phalloidin staining. Unstimulated siRNA
control-transfected 5637 cells showed a well-organized
F-actin network (arrows) and cortical actin (arrowhead)
(Figure 4B, SFM), which was severely compromised
after progranulin stimulation (Figure 4B, Progranulin).
Significantly, drebrin-depleted 5637 cells showed no
difference in F-actin remodeling between unstimulated
and progranulin-stimulated 5637 cells (Figure 4C),
which maintained the organized F-actin network (arrows)
and intact cortical actin (arrow heads) after progranulin
stimulation (Figure 4B).
Collectively, these results clearly suggest that
drebrin regulates progranulin-induced cell motility of
bladder cancer cells by modulating progranulin-mediated
F-actin remodeling.

implanted subcutaneously into the left and right flanks
respectively of 6 week-old Rag2–/– mice which lack in
the ability to initiate V(D)J rearrangement, leading to a
severe immunocompromised phenotype. Once tumors
were established, tumor sizes were monitored until the
largest tumor reached ~2000 mm3 in size. Importantly,
All control UMUC-3shScr cells generated tumor xenografts
in contrast to the debrin-depleted UMUC-3shDBN cells
which generated tumors only in ~30%, and in addition,
the average tumor volume was significantly smaller than
control (***p < 0.001, Figure 6A and 6B). To confirm that
the tumor xenografts had indeed reduced expression of
drebrin, we performed immunofluorescence analysis on
frozen sections of tumors after the animals were sacrificed.
Indeed, we found that drebrin levels were significantly
depleted in the UMUC-3shDBN xenografts (Figure 6C). On
the contrary, drebrin depletion did not affect progranulin
levels, which were very similar in control and drebrindepleted UMUC-3 cells (Figure 6D).
Collectively, these findings provide a strong
evidence for a role for drebrin in regulating tumor
formation in vivo and suggest a drebrin mechanism
of action which is independent of a possible effect
on progranulin levels. Because we have preliminary
evidences that progranulin depletion affects as well tumor
formation in vivo, these results additionally support
the hypothesis that drebrin functions by regulating
downstream progranulin signaling.

Drebrin modulates anchorage-independent
growth and in vivo tumor formation

Drebrin expression is upregulated in bladder
cancer tissues

To ascertain drebrin activity in bladder cancer
progression, we transfected a drebrin-specific
shRNA-expressing plasmid in UMUC-3 urothelial
carcinoma-derived cells. We choose these malignant
cells as UMUC-3 cells form colonies in soft-agar and
are tumorigenic in mice [24–27]. After selection in
puromycin-containing media, we isolated two pools (mass
cultures) of UMUC-3 cells where drebrin expression
was abolished (Figure 5A, shDBN 4 and 6) as compared
to either parental (P) or control-transfected (C) cells
(Figure 5A). Notably, the drebrin-depleted UMUC3 (UMUC-3shDBN) cells showed a markedly-attenuated
migratory ability in response to progranulin stimulation
(***p < 0.001, Figure 5B). More importantly, UMUC3shDBN cells were significantly impaired in forming colonies
in a soft-agar assay (***p < 0.001, Figure 5C), indicating
that drebrin exerts an important role in regulating
anchorage-independent growth of bladder cancer cells.
Based on this finding that drebrin regulates
anchorage-independent growth of UMUC-3 bladder
cancer cells, we generated mouse xenograft models and
investigated whether targeting drebrin could suppress the
ability of UMUC-3 cells to form tumors in vivo. UMUC-3
shScr (UMUC-3shScr) control and UMUC-3shDBN cells were

Next, we assessed whether drebrin expression
is altered in human bladder cancer. To this end, we
utilized a human bladder tumor microarray containing 45
validated cases in duplicate of various types of bladder
cancers and normal bladder tissue (AccuMax™ array).
In normal bladder tissue, drebrin was only detectable
primarily in the submucosal mesenchyme (arrows,
Figure 7A). Higher magnification view showed that
drebrin was primarily expressed by vascular smooth
muscle cells (arrows, Figure 7B) and nerves (arrowheads,
Figure 7B). Notably, in all malignant tissues examined
there was a marked upregulation of drebrin. Drebrin
was markedly elevated in the epithelial components of
both highly and poorly differentiated urothelial cancer
(Figures 7C–7H). In addition, the angiogenic component
of various bladder cancers, evident in the high grade
transitional cell carcinomas (arrows, Figures 7F and 7G),
showed enhanced expression of drebrin, suggesting that
it might be also involved in positively regulating tumor
angiogenesis. Significantly, the staining intensity index on
drebrin expression levels of urothelial carcinoma tissues
demonstrated that drebrin expression in high grade T2,
T3 and T4 tumors is significantly increased over lower
grade (Ta, T1) (**p < 0.01) and normal bladder tissues
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Figure 4: Drebrin is critical for progranulin-mediated F-actin remodeling. (A) GFP-tagged wild type drebrin construct has

been previously described [23]. (ADF-H) actin-depolymerizing factor homology domain. AB: actin binding domain. AE: adult specific
exon. 5637 cells were transiently transfected with the GFP-tagged drebrin construct, serum-starved for 24 h and then stimulated with
progranulin (40 nM) for 30 min. F-actin structures were assesses by immunofluorescence analysis as described in Material and Methods
using Rhodamine-phalloidin. Pictures are representative of at least 10 independent fields from three independent experiments. An average
of 300 cells was examined for each condition. Arrows indicate various F-actin structures. 5637 cells were transiently transfected with
control oligos (B) or On-Target siGenome pool of drebrin-specific oligos (Dharmacon) (C) serum-starved for 24 h and stimulated with
progranulin (40 nM) for 30 min. Immunofluorescence analysis was performed as described in Material and Methods. F-actin was detected
using anti-phalloidin staining. Drebrin levels were analyzed using anti-drebrin monoclonal antibodies. Pictures are representative of at
least 10 independent fields from three independent experiments. An average of 300 cells was examined for each condition. Arrows indicate
F-actin networks while arrowheads identify cortical actin.
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Figure 5: Stable depletion of endogenous drebrin in tumorigenic UMUC-3 urothelial cancer cells inhibits motility and
anchorage-independent growth. (A) The generation of UMUC-3/pRS-control and UMUC-3/pRS-shDBN cells has been described

in Materials and Methods. Drebrin expression in lysates from parental (P), control- (C) or shRNA drebrin-transfected (shDBN) UMUC-3
cells was detected by immunoblot. (B) Migration of the various UMUC-3 cell lines was performed using transwells as described in detail in
Materials and Methods. The experiment is the average of three independent experiments run in duplicates ±SD. **P < 0.01. ***P < 0.001.
(C) Anchorage-independent growth was measured by colony formation in soft-agar as previously described [10]. Colonies > 150 μM were
counted. The experiment is the average of three independent experiments run in duplicates ±SD. ***P < 0.001.
www.impactjournals.com/oncotarget
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Figure 6: Drebrin regulates tumor formation in vivo. (A) Tumor growth plot of mice (n = 18) injected with UMUC-3/sh-control

(shCon) and UMUC-3/sh-drebrin (shDBN) cells at day 52. ***P < 0.001. (B) Representative macroscopic photographs of UMUC-3 control
(shCon) and drebrin-depleted (shDBN) tumors at day 52. (C and D) Tumors extracted from UMUC-3/sh-control (shCon) and UMUC-3/
sh-drebrin-injected (shDBN) mice were analyzed for drebrin (C) and progranulin (D) expression by immunofluorescence analysis.
Three-dimensional surface plots are indicative of drebrin (C) and progranulin (D) expression levels in the relative fluorescence images.
Accompanying scale bars on the right depict signal intensity.
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Figure 7: Drebrin is upregulated in bladder cancer tissues. (A–H), Panels of light micrographs depicting the distribution of
immunoreactive drebrin in normal bladder (A and B) and various types of urinary cancers as indicated (C–H) Notice that in normal
bladder, drebrin is essentially not expressed in the mucosa (Mu, a) but is expressed in the submucosal blood vessels and nerves (arrows
and arrowheads, respectively, panel B). Drebrin is expressed at high levels in the epithelial components of all cancers (Ca) studied and
often in the tumor vasculature (arrows in panels f and g). Bars = 100 μm. (I) Quantification of the drebrin staining was done using ImageJ
software. Various images of normal (n = 9); Ta, T1 (n = 10) and T2, T3, T4 (n = 13) urothelial carcinoma tissues were analyzed. Briefly, the
threshold of each image was adjusted in order to show only the specific staining. The representative areas of staining were then quantified
and plot using SigmaPlot. (L–J) Drebrin and progranulin expression in frozen high grade urothelial carcinoma tissues was analyzed
by immunofluorescence analysis. Arrows (L) indicate some areas of colocalization. Three-dimensional surface plots are indicative of
progranulin (M) and drebrin (N) expression levels in the relative fluorescence images.
fewer and smaller tumors in immunocompromised animals
than the corresponding wild-type cells. Finally, we show
that drebrin expression in upregulated in several human
bladders cancers. Both highly and poorly differentiated
bladder cancers express high levels of drebrin in the tumor
proper. Notably, drebrin expression in high grade T2, T3
and T4 tumors is significantly increased over lower grade
(Ta, T1) and normal bladder tissues.
Debrin was originally identified in the brain
of chick embryos [20, 28] and it is expressed in two
isoforms: an embryonic type (drebrin E) and an adult type
(drebrin A), whose sequence is almost identical except
for an internal insert sequence in drebrin A, but no clear
functional differences have be so far described [20]. Most
of the past work on drebrin expression and activity has
been focused on neurons, in which drebrin binds F-actin
and controls actin filament dynamics, neurite morphology
and outgrowth [23, 29]. By affecting actin remodeling,
drebrin plays a significant role in regulating cell motility
in the physiology [30–32] and pathology of neuronal cells
[33]. Drebrin expression has been more recently detected
in non-neuronal tissues and cells, including stomach and
kidney epithelia [34] and T cells, where drebrin binds
the chemokine receptor CXCR4 and regulates immune
synapsis [35].

(***p < 0.001) (Figure 7I). In addition progranulin
and drebrin expression partially colocalized in high
grade urothelial carcinoma tissues, as demonstrated by
immunofluorescence analysis on a frozen high grade
urothelial carcinoma tissue (Figure 7J–7L).

DISCUSSION
We have discovered a novel interaction between
the growth factor progranulin and the F-actin-binding
protein drebrin and provide several lines of evidence that
underscore a key role for drebrin in regulating progranulin
bioactivity in bladder cancer. First, we show that drebrin is
expressed in urothelial carcinoma-derived cell lines where
it associates with progranulin as demonstrated by pulldown experiments, proteomic approaches, coimmuno
precipitation assays and colocalization experiments using
confocal laser microscopy. Second, we show for the first
time that drebrin is required for progranulin-induced
motility, invasion and activation of the Akt/MAPK
pathways in two malignant urothelial cells. Third, we
provide robust evidence that drebrin regulates progranulindependent F-actin remodeling and that this bioactivity
also requires drebrin expression. Fourth, we show that
tumorigenic UMUC-3 cells stably depleted in drebrin form
www.impactjournals.com/oncotarget
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from the cell membrane. However, the mechanisms
regulating progranulin uptake and endocytosis are very
poorly characterized, especially in bladder cancer cells.
As we mentioned in the Introduction, in neuronal cells
progranulin interacts with sortilin, which promotes
progranulin internalization and targeting for lysosomal
degradation [14]. We have discovered that sortilin is
expressed in urothelial cancer cell lines suggesting that
sortilin might complex with progranulin and drebrin in
early endocytic compartments and may play any role in
modulating early events of progranulin signaling.
Our studies point out to a very important role
for drebrin in regulating bladder cancer initiation and
progression. Drebrin is essential for progranulin-induced
signaling of urothelial cancer cells as in fact drebrin
depletion significantly inhibits the activation of both
the Akt and MAPK pathways, which are essential for
progranulin-dependent motility and invasion of urothelial
cancer cells [10, 11]. More importantly, drebrin depletion
profoundly affects the ability of urothelial cancer cells
to grow in anchorage-independency and form tumors in
xenograft models suggesting the possibility that drebrin
may not only affect progranulin-dependent responses but
also regulate additional pathways, which may converge
with progranulin signaling thereby promoting bladder
tumor initiation and possibly progression.
There is a great interest at the moment in the
identification of novel biomarkers for prognosis and
treatment selection of advanced bladder cancers [38–40].
Our results demonstrated drebrin overexpression in
various bladder cancer tissues and drebrin levels are
enhanced in high grade urothelial carcinoma compared
to lower grade and normal urothelial tissue controls. In
addition drebrin partially colocalized with progranulin
in high grade urothelial carcinoma tissues. These results
suggest that drebrin expression in bladder cancer tissue
may work in conjunction with progranulin levels as a
novel biomarker for bladder cancer and may identify
tumors likely to progress to the invasive phenotype.
However, additional studies including the analysis of
metastatic bladder cancer tissue samples are required to
clearly establish a role for drebrin in tumor progression.
In summary, our studies have identified the F-actin
protein drebrin as a novel progranulin interacting protein
critical for motility, invasion, anchorage-independent
growth and tumor formation in vivo of urothelial cancer
cells. Drebrin may constitute therefore a novel target for
therapeutic intervention in bladder tumors.

Our current findings provide the first evidence of
drebrin expression and interaction with the growth factor
progranulin in urothelial-carcinoma derived cells where
drebrin exerts an essential role in modulating progranulininduced biological responses.
The progranulin-interactive drebrin fragment we
isolated by mass spectrometry is conserved between drebrin
A and E isoforms, and the anti-drebrin antibodies used in
these studies do not discriminate between the different
drebrin isoforms. However, because drebrin A is considered
the neuron-specific isoform, while drebrin E expression
is more ubiquitous [36], we can reasonably assume that
bladder cancer cell lines likely express drebrin E. We have
transiently expressed both drebrin isoforms in 5637 cells
and we could not detect any differences in their ability to
regulate progranulin-dependent F-actin remodeling.
Our previous work has established an essential role
for progranulin in modulating migration and invasion
of bladder cancer cells. Progranulin acts as an autocrine
growth factor and regulates motility in part by activating
paxillin and promoting paxillin colocalization with FAK
at dynamic focal adhesion sites at the leading edge of
migrating cells [10, 11]. Notably, progranulin stimulation
of 5637 urothelial cancer cells does not significantly
enhance cell proliferation [9] indicating that the ability of
progranulin to promote cell motility is dissociated from a
potential effect on cell growth.
Progranulin stimulation of 5637 cells induces drebrin
redistribution at previously described F-actin spikes [23],
which are morphologically very similar to dynamic adhesions
at the membrane edge of motile 5637 cells [10, 11]. Thus,
we propose that drebrin, by regulating F-actin remodeling,
would modulate progranulin-dependent focal adhesion
turnover of migrating bladder cancer cells. However, whether
drebrin functionally interacts with paxillin and/or FAK at
focal adhesions remains to be established. Significantly,
recent experiments from our laboratories have demonstrated
that the FAK homolog Proline-Rich Tyrosine Kinase 2
(Pyk2) is upregulated in bladder cancer tissues compared
to normal tissue controls and plays a more important role
than FAK in regulating IGF-I-induced motility and invasion
of urothelial carcinoma cells [37]. We have preliminary
evidence supporting a role of Pyk2 in progranulin-dependent
signaling of urothelial cancer cells; however, it remains to
be established whether Pyk2 would interact with drebrin
and contribute with drebrin to the regulation of F-actin
remodeling and/or focal adhesion turnover.
A limitation of our studies is that, although we
have demonstrated by several independent approaches
that progranulin interacts with drebrin, we cannot
totally exclude the possibility that this interaction may
not be direct but mediated through the formation of a
multiprotein complex, which may regulate early events of
progranulin signaling. As drebrin is not a trans-membrane
protein, the interaction with progranulin is likely
occurring at early stages of progranulin internalization
www.impactjournals.com/oncotarget

MATERIALS AND METHODS
Cell lines
Urothelial carcinoma-derived human 5637, T24 and
UMUC-3 cells were obtained by ATCC (Manassas, VA,
USA).
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5637 and T24 cells were maintained in RPMI
medium with 10% fetal bovine serum (FBS). UMUC3 cells were maintained in MEM with EARL medium
with 10% FBS. Serum-free medium (SFM) is DMEM
supplemented with 0.1% bovine serum albumin and 50
μg/ml of transferrin (Sigma-Aldrich, St Louis, MO, USA).

immunoblot using anti-progranulin polyclonal antibodies
(USBiologicals) while drebrin expression was detected
using either anti-drebrin polyclonal antibodies (SigmaAldrich) or anti-drebrin monoclonal antibodies (Abcam).

Pull-down assays with recombinant progranulin
and proteomic analysis

Transient depletion of endogenous drebrin in 5637
and T24 cells was achieved by siRNA approaches using
vehicle, control oligos or On-Target siGenome pool of
drebrin-specific oligos (Dharmacon, Lafayette, CO, USA).
Cells were transfected with 400 pM of oligos using the
TransIT-TKO® Transfection Reagent (Mirus, Madison,
WI, USA). Biological responses and drebrin expression
levels were assessed after 72 h post-transfection.

Drebrin depletion by siRNA approaches

Serum-starved 5637 cells were stimulated with
progranulin (40 nM) for 5 min and lysates collected in
NP-40 lysis buffer containing Protease and Phosphatase
Inhibitor Cocktail (Thermo Scientifics, Waltham, MA
USA). After preclearing for 1 h with Ni-NTA-agarose
beads (QIAGEN, Valencia, CA, USA), lysates (10 mg)
were first incubated with or without 7 μg of recombinant
HIS-tagged progranulin overnight a 4oC and then with
Ni-NTA-agarose beads for 1 h. Beads were washed with
lysis buffer and resuspended in Laemmli buffer. Samples
were separated by SDS-PAGE, visualized with Coomassie
blue staining and processed for mass spectrometry at the
Proteomic Core Facility of the Kimmel Cancer Center.
Bands were excised and digested with trypsin after
reduction and alkylation. Peptides were separated on a
10-cm C18 column and analyzed on a Thermo LCQ 3D ion
trap using the nano-source. MS/MS spectra were searched
on a local Mascot server against the Swissprot database. All
peptides were identified with a confidence of at least 95%.

Migration, wound healing and invasion assays
HTS FluoroBloks™ inserts (Becton Dickinson,
Durham, NC, USA) were saturated with PBS-1% bovine
serum albumin for 2 h at room temperature. Serumstarved cells were labeled with DiI (Molecular Probes,
Grand Island, NY, USA) for 20 min at 37°C and seeded
in the HTS FluoroBloks™ upper chamber in SFM
or SFM supplemented with progranulin (40 nM) and
incubated at 37°C for 18 h. Membranes were fixed in 4%
paraformaldehyde, mounted on slides and migrated cells
were counted and photographed with a Zeiss Axiovert
200 M cell live microscope. Cell invasion was assessed
by using BD Matrigel™ Invasion Chambers (BD Biocoat,
Bedford, MA, USA) with 8.0 μm filter membranes. Cells
(5x104) in 200 μl of SFM were plated onto each filter, and
750 μl of SFM or SFM supplemented with progranulin (40
nM) in the lower chamber. After 24 h filters were washed,
fixed, and stained with Coomassie Brilliant Blue. Cells on
the upper surface of the filters were removed with cotton
swabs. Cells that had invaded to the lower surface of the
filter were counted under the microscope.

Confocal microscopy
5637 cells on slides were serum-starved overnight
and treated with progranulin (40 nM) for 5 min. Cells were
then washed with PBS and fixed with 4% PFA for 30 min
at room temperature. Subsequently, slides were subjected
to immunofluorescence and confocal analysis as previously
described [9, 10, 37, 41–43]. Primary antibodies were antiprogranulin polyclonal (USBiologicals, Swampscott, MA,
USA) and anti-drebrin monoclonal antibodies (Abcam,
Cambridge, MA, USA). Secondary antibodies were goat
anti-mouse IgG Alexa Fluor® 488 and goat anti-rabbit IgG
Alexa Fluor® 594 antibodies (Invitrogen, Grand Island, NY,
USA). Confocal analysis was carried out using a 63x, 1.3
oil-immersion objective of a Zeiss LSM-78 confocal laserscanning microscope. To determine colocalization of the
two proteins, Z-stack series were acquired maintaining the
same slice interval. All images were analyzed using ImageJ
and Adobe Photoshop CS6 (Adobe Systems). Line scanning
plots were performed utilizing SigmaPlot software.

Immunoblot detection of activated signaling
pathways
Serum-starved cells were then stimulated with
progranulin (40 nM) for 10 min. The activation of Akt
and ERK1/2 was analyzed by western immunoblot using
phospho-specific antibodies (Cell Signaling Technology,
Beverly, MA, USA) as described [44]. Total levels of Akt
and ERKs were monitored with anti-Akt and anti-ERK1/2
antibodies (Cell Signaling Technology).

Drebrin expression and F-actin remodeling

Co-immunoprecipitation and immunoblotting

The GFP-drebrin fusion proteins GFP-drebrin A wt
was previously described [23]. 5637 cells were transfected
on slides using the TransIT®-Prostate Transfection Kit
(Mirus). 48 h after transfection, cells were serum-starved
for 24 h and then treated with either 1X PBS or 40 nM

Serum-starved 5637 and T24 cells were stimulated
for 5 and 30 min with 80 nM progranulin and lysates (3
mg) immunoprecipitated with anti-progranulin polyclonal
antibodies (USBiologicals). Progranulin was detected by
www.impactjournals.com/oncotarget
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of progranulin for 30 min. Cells were fixed for 30 min
at room temperature with 4% paraformaldehyde in 1X
PBS and permeabilized for 30 seconds with 0.01%
Tween in 1X PBS. F-actin staining was assessed by
Rhodamine-phalloidin (Invitrogen) for 20 min and then
fixed with Vectashield (Vector, Burlingame, CA, USA).
Drebrin expression was detected using an anti-drebrin
polyclonal antibody (Sigma-Aldrich) followed by a goat
anti-rabbit IgG Alexa-Fluor 594 secondary antibody.
Immunofluorescence analysis was performed using a
LEICA DM5500B fluorescent microscope.

high grade human bladder tissue using anti-drebrin and
progranulin antibodies described above. Three-dimensional
surface plots were created with ImageJ and represent
drebrin and/or progranulin expression based on the intensity
of the immunofluorescence signal.

Immunohistochemical detection of drebrin in
bladder cancer tissues
Drebrin expression was analyzed by immuno
histochemistry on an AccuMax™ bladder cancer tissue
microarray (Petagen Inc., Seodaemun-gu, Seoul, Korea)
at the Translational Core Facility of the Kimmel Cancer
Center. The anti-drebrin monoclonal antibody was used
at a 1:200 dilution. Detailed specifications of the bladder
tissue array can be found at: tissuearray.petagen.com/
main/products.php?no=110.
Quantification of the drebrin staining in urothelial
carcinoma tissues was done using ImageJ software. Various
images of normal (n = 9); Ta, T1 (n = 10) and T2, T3, T4
(n = 13) urothelial carcinoma tissues were analyzed. Briefly,
the threshold of each image was adjusted in order to show
only the specific staining. The representative areas of
staining were then quantified and plot using SigmaPlot.

Generation of progranulin-depleted UMUC-3
cells
UMUC-3 cells stably depleted of endogenous
drebrin were generated by transfecting the pRS vector,
the pRS-shRNA-control (scrambled shRNA) and pRS/
shDBN plasmids (OriGene Technologies, Inc., Rockville,
MD, USA) using the TransIT®-Prostate Transfection Kit
(Mirus). Cells were selected in medium supplemented
with 2 μg/ml of Puromycin. After selection, pools of
drebrin-depleted UMUC-3 cells were tested for drebrin
expression levels by immunoblot using anti-drebrin
monoclonal antibodies (Abcam).

Statistical analysis

Colony formation assay in soft-agar

Results of multiple experiments are expressed as
mean ± SD. All statistical analyses were carried out with
SigmaStat for Windows version 3.10 (Systat Software,
Inc., Port Richmond, CA). Results were compared using
the two-sided Student’s t test. Differences were considered
statistically significant at p < 0.05.

Colony formation in soft-agar was performed as
previously described [10]. Cells were counted after four
weeks in culture. Colonies > 150 μm were scored as positive.

Tumor xenografts
Experiments using 7- to 10-week-old Rag2–/–
mice were carried out according to protocols approved
by the Institutional Review Board of Thomas Jefferson
University. 4 × 106 UMUC-3/sh-control and sh-drebrin
cells were injected subcutaneously in two distinct sites
of mice flanks (control cells in the upper-left flank and
drebrin-depleted cells in the lower-right flank). Three
independent experiments with 6 mice each were performed
(n = 18). Once tumors were established, tumor growth was
measured every 2 days with a micro-caliper utilizing the
following formula: V = a(b2/2), where a and b represent
the larger and small diameters, respectively. When tumors
reached 2000 mm3 in size, mice were sacrificed and tumors
surgically dissected and divided. One half was snap frozen
in liquid nitrogen for further biochemical analysis, whereas
the other half was embedded in OCT medium (Sakura
Finetek, Torrance, CA, USA) and frozen at –20°C. 10 μm
thick cryostat sections were cut from the blocks, mounted
on slides and subjected to immunofluorescence analysis
utilizing a mouse monoclonal anti-drebrin antibody (Santa
Cruz, Dallas, Texas, USA).
Colocalization of progranulin and drebrin was
assessed by immunofluorescence analysis on an unidentified
www.impactjournals.com/oncotarget
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